{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:57:35Z","timestamp":1791863855665,"version":"4.3.4"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Yunnan Basic Research Program - Joint Project of Kunming Medical University","award":["202301AY070001-249"],"award-info":[{"award-number":["202301AY070001-249"]}]},{"name":"Yunnan Provincial Department of Science and Technology Foundation for Youths","award":["202301AU070195"],"award-info":[{"award-number":["202301AU070195"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"DOI":"10.1186\/s13148-025-02010-y","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T15:29:46Z","timestamp":1763738986000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Lysine demethylases 6\u00a0A and 6B as epigenetic regulators in therapeutic resistance of cancer"],"prefix":"10.1186","volume":"17","author":[{"given":"Linzhu","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haohan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuchao","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangcan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"2010_CR1","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nrg.2016.59","volume":"17","author":"CD Allis","year":"2016","unstructured":"Allis CD, Jenuwein T. The molecular hallmarks of epigenetic control. Nat Rev Genet. 2016;17:487\u2013500. https:\/\/doi.org\/10.1038\/nrg.2016.59.","journal-title":"Nat Rev Genet"},{"key":"2010_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41392-019-0095-0","volume":"4","author":"Y Cheng","year":"2019","unstructured":"Cheng Y, He C, Wang M, Ma X, Mo F, Yang S, Han J, Wei X. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct Target Ther. 2019;4:62. https:\/\/doi.org\/10.1038\/s41392-019-0095-0.","journal-title":"Signal Transduct Target Ther"},{"key":"2010_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13148-016-0223-4","volume":"8","author":"L Morera","year":"2016","unstructured":"Morera L, L\u00fcbbert M, Jung M. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy. Clin Epigenetics. 2016;8:57. https:\/\/doi.org\/10.1186\/s13148-016-0223-4.","journal-title":"Clin Epigenetics"},{"key":"2010_CR4","doi-asserted-by":"publisher","first-page":"e324","DOI":"10.1038\/emm.2017.11","volume":"49","author":"K Hyun","year":"2017","unstructured":"Hyun K, Jeon J, Park K, Kim J. Writing, erasing and reading histone lysine methylations. Exp Mol Med. 2017;49:e324. https:\/\/doi.org\/10.1038\/emm.2017.11.","journal-title":"Exp Mol Med"},{"key":"2010_CR5","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s13059-019-1870-5","volume":"20","author":"Z Zhao","year":"2019","unstructured":"Zhao Z, Shilatifard A. Epigenetic modifications of histones in cancer. Genome Biol. 2019;20:245. https:\/\/doi.org\/10.1186\/s13059-019-1870-5.","journal-title":"Genome Biol"},{"key":"2010_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/ng1089","volume":"33","author":"R Jaenisch","year":"2003","unstructured":"Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet. 2003;33:245\u201354. https:\/\/doi.org\/10.1038\/ng1089.","journal-title":"Nat Genet"},{"key":"2010_CR7","doi-asserted-by":"publisher","first-page":"a019521","DOI":"10.1101\/cshperspect.a019521","volume":"8","author":"JE Audia","year":"2016","unstructured":"Audia JE, Campbell RM. Histone modifications and cancer. Cold Spring Harb Perspect Biol. 2016;8:a019521. https:\/\/doi.org\/10.1101\/cshperspect.a019521.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2010_CR8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nrg3173","volume":"13","author":"EL Greer","year":"2012","unstructured":"Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet. 2012;13:343\u201357. https:\/\/doi.org\/10.1038\/nrg3173.","journal-title":"Nat Rev Genet"},{"key":"2010_CR9","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.biocel.2015.07.006","volume":"67","author":"JS Burchfield","year":"2015","unstructured":"Burchfield JS, Li Q, Wang HY, Wang RF. JMJD3 as an epigenetic regulator in development and disease. Int J Biochem Cell Biol. 2015;67:148\u201357. https:\/\/doi.org\/10.1016\/j.biocel.2015.07.006.","journal-title":"Int J Biochem Cell Biol"},{"key":"2010_CR10","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nrg1945","volume":"7","author":"RJ Klose","year":"2006","unstructured":"Klose RJ, Kallin EM, Zhang Y. JmjC-domain-containing proteins and histone demethylation. Nat Rev Genet. 2006;7:715\u201327. https:\/\/doi.org\/10.1038\/nrg1945.","journal-title":"Nat Rev Genet"},{"key":"2010_CR11","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s00109-014-1182-x","volume":"92","author":"A Salminen","year":"2014","unstructured":"Salminen A, Kaarniranta K, Hiltunen M, Kauppinen A. Histone demethylase Jumonji D3 (JMJD3\/KDM6B) at the nexus of epigenetic regulation of inflammation and the aging process. J Mol Med (Berl). 2014;92:1035\u201343. https:\/\/doi.org\/10.1007\/s00109-014-1182-x.","journal-title":"J Mol Med (Berl)"},{"key":"2010_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12943-021-01369-9","volume":"20","author":"L Liu","year":"2021","unstructured":"Liu L, Cui J, Zhao Y, Liu X, Chen L, Xia Y, Wang Y, Chen S, Sun S, Shi B, Zou Y. KDM6A-ARHGDIB axis blocks metastasis of bladder cancer by inhibiting Rac1. Mol Cancer. 2021;20:77. https:\/\/doi.org\/10.1186\/s12943-021-01369-9.","journal-title":"Mol Cancer"},{"key":"2010_CR13","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature12912","volume":"505","author":"MS Lawrence","year":"2014","unstructured":"Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES, Getz G. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505:495\u2013501. https:\/\/doi.org\/10.1038\/nature12912.","journal-title":"Nature"},{"key":"2010_CR14","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.phrs.2016.01.026","volume":"105","author":"SY Park","year":"2016","unstructured":"Park SY, Park JW, Chun YS. Jumonji histone demethylases as emerging therapeutic targets. Pharmacol Res. 2016;105:146\u201351. https:\/\/doi.org\/10.1016\/j.phrs.2016.01.026.","journal-title":"Pharmacol Res"},{"key":"2010_CR15","doi-asserted-by":"publisher","first-page":"106409","DOI":"10.1016\/j.bioorg.2023.106409","volume":"133","author":"LJ Chen","year":"2023","unstructured":"Chen LJ, Xu XY, Zhong XD, Liu YJ, Zhu MH, Tao F, Li CY, She QS, Yang GJ, Chen J. The role of lysine-specific demethylase 6A (KDM6A) in tumorigenesis and its therapeutic potentials in cancer therapy. Bioorg Chem. 2023;133:106409. https:\/\/doi.org\/10.1016\/j.bioorg.2023.106409.","journal-title":"Bioorg Chem"},{"key":"2010_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.biochi.2021.02.005","volume":"184","author":"FA Lagunas-Rangel","year":"2021","unstructured":"Lagunas-Rangel FA. KDM6B (JMJD3) and its dual role in cancer. Biochimie. 2021;184:63\u201371. https:\/\/doi.org\/10.1016\/j.biochi.2021.02.005.","journal-title":"Biochimie"},{"key":"2010_CR17","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1101\/gad.172296.111","volume":"25","author":"T Sengoku","year":"2011","unstructured":"Sengoku T, Yokoyama S. Structural basis for histone H3 Lys 27 demethylation by UTX\/KDM6A. Genes Dev. 2011;25:2266\u201377. https:\/\/doi.org\/10.1101\/gad.172296.111.","journal-title":"Genes Dev"},{"key":"2010_CR18","doi-asserted-by":"publisher","unstructured":"Schniewind I, Besso MJ, Klicker S, Schwarz FM, Hadiwikarta WW, Richter S, L\u00f6ck S, Linge A, Krause M, Dubrovska A, Baumann M, Kurth I, Peitzsch C. Epigenetic targeting to overcome radioresistance in head and neck cancer. Cancers (Basel). 2024;16. https:\/\/doi.org\/10.3390\/cancers16040730.","DOI":"10.3390\/cancers16040730"},{"key":"2010_CR19","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1038\/s41388-024-03029-w","volume":"43","author":"M Feng","year":"2024","unstructured":"Feng M, Chai C, Hao X, Lai X, Luo Y, Zhang H, Tang W, Gao N, Pan G, Liu X, Wang Y, Xiong W, Wu Q, Wang J. Inherited KDM6A(A649T) facilitates tumor-immune escape and exacerbates colorectal signet-ring cell carcinoma outcomes. Oncogene. 2024;43:1757\u201368. https:\/\/doi.org\/10.1038\/s41388-024-03029-w.","journal-title":"Oncogene"},{"key":"2010_CR20","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1186\/s12885-021-08372-9","volume":"21","author":"X Chen","year":"2021","unstructured":"Chen X, Lin X, Pang G, Deng J, Xie Q, Zhang Z. Significance of KDM6A mutation in bladder cancer immune escape. BMC Cancer. 2021;21:635. https:\/\/doi.org\/10.1186\/s12885-021-08372-9.","journal-title":"BMC Cancer"},{"key":"2010_CR21","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13148-022-01305-8","volume":"14","author":"J Abu-Hanna","year":"2022","unstructured":"Abu-Hanna J, Patel JA, Anastasakis E, Cohen R, Clapp LH, Loizidou M, Eddama MMR. Therapeutic potential of inhibiting histone 3 lysine 27 demethylases: a review of the literature. Clin Epigenetics. 2022;14:98. https:\/\/doi.org\/10.1186\/s13148-022-01305-8.","journal-title":"Clin Epigenetics"},{"key":"2010_CR22","doi-asserted-by":"publisher","unstructured":"Yang G-J, Liu Y-J, Ding L-J, Tao F, Zhu M-H, Shi Z-Y, Wen J-M, Niu M-Y, Li X, Xu Z-S, Qin W-J, Fei C-J, Chen J. A state-of-the-art review on LSD1 and its inhibitors in breast cancer: molecular mechanisms and therapeutic significance. Front Pharmacol. 2022;13. https:\/\/doi.org\/10.3389\/fphar.2022.989575.","DOI":"10.3389\/fphar.2022.989575"},{"key":"2010_CR23","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.3390\/molecules23123194","volume":"23","author":"G-J Yang","year":"2018","unstructured":"Yang G-J, Lei P-M, Wong S-Y, Ma D-L, Leung C-H. Pharmacological Inhibition of LSD1 for cancer treatment. Molecules. 2018;23:3194.","journal-title":"Molecules"},{"key":"2010_CR24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13045-021-01041-1","volume":"14","author":"G-J Yang","year":"2021","unstructured":"Yang G-J, Zhu M-H, Lu X-J, Liu Y-J, Lu J-F, Leung C-H, Ma D-L, Chen J. The emerging role of KDM5A in human cancer. J Hematol Oncol. 2021;14:30. https:\/\/doi.org\/10.1186\/s13045-021-01041-1.","journal-title":"J Hematol Oncol"},{"key":"2010_CR25","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ccell.2019.01.001","volume":"35","author":"L Wang","year":"2019","unstructured":"Wang L, Shilatifard A. UTX mutations in human cancer. Cancer Cell. 2019;35:168\u201376. https:\/\/doi.org\/10.1016\/j.ccell.2019.01.001.","journal-title":"Cancer Cell"},{"key":"2010_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0230-6","volume":"51","author":"S Chang","year":"2019","unstructured":"Chang S, Yim S, Park H. The cancer driver genes IDH1\/2, JARID1C\/ KDM5C, and UTX\/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism. Exp Mol Med. 2019;51:1\u201317. https:\/\/doi.org\/10.1038\/s12276-019-0230-6.","journal-title":"Exp Mol Med"},{"key":"2010_CR27","doi-asserted-by":"crossref","unstructured":"Walport LJ, Hopkinson RJ, Vollmar M, Madden SK, Gileadi C, Oppermann U, Schofield CJ, Johansson C. Human UTY(KDM6C) Is a Male-specific\u2009<\u2009em\u2009>\u2009N\u2009<\u2009sup>\u03f5-Methyl Lysyl Demethylase *. Journal of Biological Chemistry 2014; 289: 18302\u201318313. https:\/\/doi.org\/10.1074\/jbc.M114.555052","DOI":"10.1074\/jbc.M114.555052"},{"key":"2010_CR28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.gde.2016.03.010","volume":"36","author":"KM Arcipowski","year":"2016","unstructured":"Arcipowski KM, Martinez CA, Ntziachristos P. Histone demethylases in physiology and cancer: a Tale of two enzymes, JMJD3 and UTX. Curr Opin Genet Dev. 2016;36:59\u201367. https:\/\/doi.org\/10.1016\/j.gde.2016.03.010.","journal-title":"Curr Opin Genet Dev"},{"key":"2010_CR29","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.cmet.2015.06.023","volume":"22","author":"AM Intlekofer","year":"2015","unstructured":"Intlekofer AM, Dematteo RG, Venneti S, Finley LW, Lu C, Judkins AR, Rustenburg AS, Grinaway PB, Chodera JD, Cross JR, Thompson CB. Hypoxia induces production of L-2-Hydroxyglutarate. Cell Metab. 2015;22:304\u201311. https:\/\/doi.org\/10.1016\/j.cmet.2015.06.023.","journal-title":"Cell Metab"},{"key":"2010_CR30","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1126\/science.aaw8373","volume":"363","author":"P Gallipoli","year":"2019","unstructured":"Gallipoli P, Huntly BJP. Histone modifiers are oxygen sensors. Science. 2019;363:1148\u20139. https:\/\/doi.org\/10.1126\/science.aaw8373.","journal-title":"Science"},{"key":"2010_CR31","doi-asserted-by":"publisher","first-page":"5497","DOI":"10.1038\/onc.2017.157","volume":"36","author":"G Xie","year":"2017","unstructured":"Xie G, Liu X, Zhang Y, Li W, Liu S, Chen Z, Xu B, Yang J, He L, Zhang Z, Jin T, Yi X, Sun L, Shang Y, Liang J. UTX promotes hormonally responsive breast carcinogenesis through feed-forward transcription regulation with Estrogen receptor. Oncogene. 2017;36:5497\u2013511. https:\/\/doi.org\/10.1038\/onc.2017.157.","journal-title":"Oncogene"},{"key":"2010_CR32","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1128\/mcb.00839-14","volume":"34","author":"L Rocha-Viegas","year":"2014","unstructured":"Rocha-Viegas L, Villa R, Gutierrez A, Iriondo O, Shiekhattar R, Di Croce L. Role of UTX in retinoic acid receptor-mediated gene regulation in leukemia. Mol Cell Biol. 2014;34:3765\u201375. https:\/\/doi.org\/10.1128\/mcb.00839-14.","journal-title":"Mol Cell Biol"},{"key":"2010_CR33","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/onc.2012.48","volume":"32","author":"M Jan","year":"2013","unstructured":"Jan M, Majeti R. Clonal evolution of acute leukemia genomes. Oncogene. 2013;32:135\u201340. https:\/\/doi.org\/10.1038\/onc.2012.48.","journal-title":"Oncogene"},{"key":"2010_CR34","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1158\/1078-0432.Ccr-17-2344","volume":"24","author":"PA Greif","year":"2018","unstructured":"Greif PA, Hartmann L, Vosberg S, Stief SM, Mattes R, Hellmann I, Metzeler KH, Herold T, Bamopoulos SA, Kerbs P, Jurinovic V, Schumacher D, Pastore F, Br\u00e4undl K, Zellmeier E, Ksienzyk B, Konstandin NP, Schneider S, Graf A, Krebs S, Blum H, Neumann M, Baldus CD, Bohlander SK, Wolf S, G\u00f6rlich D, Berdel WE, W\u00f6rmann BJ, Hiddemann W, Spiekermann K. Evolution of cytogenetically normal acute myeloid leukemia during therapy and relapse: an exome sequencing study of 50 patients. Clin Cancer Res. 2018;24:1716\u201326. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-2344.","journal-title":"Clin Cancer Res"},{"key":"2010_CR35","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41375-019-0497-6","volume":"34","author":"SM Stief","year":"2020","unstructured":"Stief SM, Hanneforth AL, Weser S, Mattes R, Carlet M, Liu WH, Bartoschek MD, Dom\u00ednguez Moreno H, Oettle M, Kempf J, Vick B, Ksienzyk B, Tizazu B, Rothenberg-Thurley M, Quentmeier H, Hiddemann W, Vosberg S, Greif PA, Metzeler KH, Schotta G, Bultmann S, Jeremias I, Leonhardt H, Spiekermann K. Loss of KDM6A confers drug resistance in acute myeloid leukemia. Leukemia. 2020;34:50\u201362. https:\/\/doi.org\/10.1038\/s41375-019-0497-6.","journal-title":"Leukemia"},{"key":"2010_CR36","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/onc.2017.309","volume":"37","author":"N Venkatesan","year":"2018","unstructured":"Venkatesan N, Wong JF, Tan KP, Chung HH, Yau YH, Cukuroglu E, Allahverdi A, Nordenski\u00f6ld L, G\u00f6ke J, Geifman-Shochat S, Lin VCL, Madhusudhan MS, Su IH. EZH2 promotes neoplastic transformation through VAV interaction-dependent extranuclear mechanisms. Oncogene. 2018;37:461\u201377. https:\/\/doi.org\/10.1038\/onc.2017.309.","journal-title":"Oncogene"},{"key":"2010_CR37","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/bju.12702","volume":"117","author":"L Liu","year":"2016","unstructured":"Liu L, Xu Z, Zhong L, Wang H, Jiang S, Long Q, Xu J, Guo J. Enhancer of Zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma. BJU Int. 2016;117:351\u201362. https:\/\/doi.org\/10.1111\/bju.12702.","journal-title":"BJU Int"},{"key":"2010_CR38","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1038\/s41418-019-0278-9","volume":"26","author":"S Ramakrishnan","year":"2019","unstructured":"Ramakrishnan S, Granger V, Rak M, Hu Q, Attwood K, Aquila L, Krishnan N, Osiecki R, Azabdaftari G, Guru K, Chatta G, Gueron G, McNally L, Ohm J, Wang J, Woloszynska A. Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer. Cell Death Differ. 2019;26:2100\u201314. https:\/\/doi.org\/10.1038\/s41418-019-0278-9.","journal-title":"Cell Death Differ"},{"key":"2010_CR39","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938\u201348. https:\/\/doi.org\/10.1056\/NEJMra1001389.","journal-title":"N Engl J Med"},{"key":"2010_CR40","doi-asserted-by":"publisher","first-page":"106","DOI":"10.7497\/j.issn.2095-3941.2015.0030","volume":"12","author":"HA Wahba","year":"2015","unstructured":"Wahba HA, El-Hadaad HA. Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med. 2015;12:106\u201316. https:\/\/doi.org\/10.7497\/j.issn.2095-3941.2015.0030.","journal-title":"Cancer Biol Med"},{"key":"2010_CR41","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1158\/1541-7786.Mcr-21-0402","volume":"20","author":"JF Xiao","year":"2022","unstructured":"Xiao JF, Kua LF, Ding LW, Sun QY, Myint KN, Chia XR, Venkatachalam N, Loh X, Duex JE, Neang V, Zhou S, Li Y, Yang H, Koeffler HP, Theodorescu D. KDM6A depletion in breast epithelial cells leads to reduced sensitivity to anticancer agents and increased TGF\u03b2 activity. Mol Cancer Res. 2022;20:637\u201349. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-21-0402.","journal-title":"Mol Cancer Res"},{"key":"2010_CR42","doi-asserted-by":"publisher","first-page":"288","DOI":"10.12688\/f1000research.10992.1","volume":"6","author":"F Moiseenko","year":"2017","unstructured":"Moiseenko F, Volkov N, Bogdanov A, Dubina M, Moiseyenko V. Resistance mechanisms to drug therapy in breast cancer and other solid tumors: an opinion. F1000Res. 2017;6:288. https:\/\/doi.org\/10.12688\/f1000research.10992.1.","journal-title":"F1000Res"},{"key":"2010_CR43","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.cell.2005.08.020","volume":"122","author":"LA Boyer","year":"2005","unstructured":"Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, Guenther MG, Kumar RM, Murray HL, Jenner RG, Gifford DK, Melton DA, Jaenisch R, Young RA. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell. 2005;122:947\u201356. https:\/\/doi.org\/10.1016\/j.cell.2005.08.020.","journal-title":"Cell"},{"key":"2010_CR44","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1172\/jci138577","volume":"130","author":"H Lu","year":"2020","unstructured":"Lu H, Xie Y, Tran L, Lan J, Yang Y, Murugan NL, Wang R, Wang YJ, Semenza GL. Chemotherapy-induced S100A10 recruits KDM6A to facilitate OCT4-mediated breast cancer stemness. J Clin Invest. 2020;130:4607\u201323. https:\/\/doi.org\/10.1172\/jci138577.","journal-title":"J Clin Invest"},{"key":"2010_CR45","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.7150\/thno.70581","volume":"12","author":"J Lan","year":"2022","unstructured":"Lan J, Wei G, Liu J, Yang F, Sun R, Lu H. Chemotherapy-induced adenosine A2B receptor expression mediates epigenetic regulation of pluripotency factors and promotes breast cancer stemness. Theranostics. 2022;12:2598\u2013612. https:\/\/doi.org\/10.7150\/thno.70581.","journal-title":"Theranostics"},{"key":"2010_CR46","doi-asserted-by":"publisher","first-page":"1716618","DOI":"10.1080\/23723556.2020.1716618","volume":"7","author":"JK Douglas","year":"2020","unstructured":"Douglas JK, Callahan RE, Hothem ZA, Cousineau CS, Kawak S, Thibodeau BJ, Bergeron S, Li W, Peeples CE, Wasvary HJ. Genomic variation as a marker of response to neoadjuvant therapy in locally advanced rectal cancer. Mol Cell Oncol. 2020;7:1716618. https:\/\/doi.org\/10.1080\/23723556.2020.1716618.","journal-title":"Mol Cell Oncol"},{"key":"2010_CR47","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.stem.2014.11.012","volume":"15","author":"A Zeuner","year":"2014","unstructured":"Zeuner A, Todaro M, Stassi G, De Maria R. Colorectal cancer stem cells: from the crypt to the clinic. Cell Stem Cell. 2014;15:692\u2013705. https:\/\/doi.org\/10.1016\/j.stem.2014.11.012.","journal-title":"Cell Stem Cell"},{"key":"2010_CR48","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc1590","volume":"5","author":"M Dean","year":"2005","unstructured":"Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275\u201384. https:\/\/doi.org\/10.1038\/nrc1590.","journal-title":"Nat Rev Cancer"},{"key":"2010_CR49","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1093\/jmcb\/mjz032","volume":"12","author":"Q Wang","year":"2020","unstructured":"Wang Q, Chen X, Jiang Y, Liu S, Liu H, Sun X, Zhang H, Liu Z, Tao Y, Li C, Hu Y, Liu D, Ye D, Liu Y, Wang M, Zhang X. Elevating H3K27me3 level sensitizes colorectal cancer to oxaliplatin. J Mol Cell Biol. 2020;12:125\u201337. https:\/\/doi.org\/10.1093\/jmcb\/mjz032.","journal-title":"J Mol Cell Biol"},{"key":"2010_CR50","doi-asserted-by":"publisher","first-page":"10016","DOI":"10.7150\/thno.47081","volume":"10","author":"J Zhang","year":"2020","unstructured":"Zhang J, Ying Y, Li M, Wang M, Huang X, Jia M, Zeng J, Ma C, Zhang Y, Li C, Wang X, Shu XS. Targeted Inhibition of KDM6 histone demethylases eradicates tumor-initiating cells via enhancer reprogramming in colorectal cancer. Theranostics. 2020;10:10016\u201330. https:\/\/doi.org\/10.7150\/thno.47081.","journal-title":"Theranostics"},{"key":"2010_CR51","doi-asserted-by":"publisher","first-page":"101778","DOI":"10.1016\/j.tranon.2023.101778","volume":"37","author":"Z Chen","year":"2023","unstructured":"Chen Z, Qi Y, Shen J, Chen Z. Histone demethylase KDM6A coordinating with KMT2B regulates self-renewal and chemoresistance of non-small cell lung cancer stem cells. Transl Oncol. 2023;37:101778. https:\/\/doi.org\/10.1016\/j.tranon.2023.101778.","journal-title":"Transl Oncol"},{"key":"2010_CR52","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.bbrc.2020.04.112","volume":"527","author":"F Wang","year":"2020","unstructured":"Wang F, Zhu Y, Wang F, Wang Y, Dong BJ, Wang N, Gao WQ. Wnt\/\u03b2-catenin signaling contributes to prostate cancer heterogeneity through reciprocal suppression of H3K27 trimethylation. Biochem Biophys Res Commun. 2020;527:242\u20139. https:\/\/doi.org\/10.1016\/j.bbrc.2020.04.112.","journal-title":"Biochem Biophys Res Commun"},{"key":"2010_CR53","doi-asserted-by":"publisher","first-page":"9043","DOI":"10.1038\/s41598-023-35950-7","volume":"13","author":"J Haldrup","year":"2023","unstructured":"Haldrup J, Weiss S, Schmidt L, S\u00f8rensen KD. Investigation of enzalutamide, docetaxel, and Cabazitaxel resistance in the castration resistant prostate cancer cell line C4 using genome-wide CRISPR\/Cas9 screening. Sci Rep. 2023;13:9043. https:\/\/doi.org\/10.1038\/s41598-023-35950-7.","journal-title":"Sci Rep"},{"key":"2010_CR54","doi-asserted-by":"publisher","first-page":"7665","DOI":"10.1093\/nar\/gkae487","volume":"52","author":"J Wu","year":"2024","unstructured":"Wu J, Jiang Y, Zhang Q, Mao X, Wu T, Hao M, Zhang S, Meng Y, Wan X, Qiu L, Han J. KDM6A-SND1 interaction maintains genomic stability by protecting the nascent DNA and contributes to cancer chemoresistance. Nucleic Acids Res. 2024;52:7665\u201386. https:\/\/doi.org\/10.1093\/nar\/gkae487.","journal-title":"Nucleic Acids Res"},{"key":"2010_CR55","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1200\/jco.2016.70.3108","volume":"35","author":"C Fung","year":"2017","unstructured":"Fung C, Sesso HD, Williams AM, Kerns SL, Monahan P, Abu Zaid M, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Kollmannsberger CK, Cook R, Althouse S, Ardeshir-Rouhani-Fard S, Lipshultz SE, Einhorn LH, Fossa SD, Travis LB. Multi-Institutional assessment of adverse health outcomes among North American testicular cancer survivors after modern Cisplatin-Based chemotherapy. J Clin Oncol. 2017;35:1211\u201322. https:\/\/doi.org\/10.1200\/jco.2016.70.3108.","journal-title":"J Clin Oncol"},{"key":"2010_CR56","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1002\/cncr.26375","volume":"118","author":"DR Feldman","year":"2012","unstructured":"Feldman DR, Patil S, Trinos MJ, Carousso M, Ginsberg MS, Sheinfeld J, Bajorin DF, Bosl GJ, Motzer RJ. Progression-free and overall survival in patients with relapsed\/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design. Cancer. 2012;118:981\u20136. https:\/\/doi.org\/10.1002\/cncr.26375.","journal-title":"Cancer"},{"key":"2010_CR57","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1186\/s12964-024-01912-3","volume":"22","author":"D Shokry","year":"2024","unstructured":"Shokry D, Khan MW, Powell C, Johnson S, Rennels BC, Boyd RI, Sun Z, Fazal Z, Freemantle SJ, Parker MH, Vieson MD, Samuelson JP, Spinella MJ, Singh R. Refractory testicular germ cell tumors are highly sensitive to the targeting of polycomb pathway demethylases KDM6A and KDM6B. Cell Commun Signal. 2024;22:528. https:\/\/doi.org\/10.1186\/s12964-024-01912-3.","journal-title":"Cell Commun Signal"},{"key":"2010_CR58","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/oxfordjournals.jbchem.a003272","volume":"132","author":"S Nakashima","year":"2002","unstructured":"Nakashima S. Protein kinase C\u03b1 (PKC\u03b1): regulation and biological function. J Biochem. 2002;132:669\u201375. https:\/\/doi.org\/10.1093\/oxfordjournals.jbchem.a003272.","journal-title":"J Biochem"},{"key":"2010_CR59","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1146\/annurev.cellbio.15.1.269","volume":"15","author":"I Budihardjo","year":"1999","unstructured":"Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol. 1999;15:269\u201390. https:\/\/doi.org\/10.1146\/annurev.cellbio.15.1.269.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"2010_CR60","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13148-018-0605-x","volume":"11","author":"C He","year":"2019","unstructured":"He C, Sun J, Liu C, Jiang Y, Hao Y. Elevated H3K27me3 levels sensitize osteosarcoma to cisplatin. Clin Epigenetics. 2019;11:8. https:\/\/doi.org\/10.1186\/s13148-018-0605-x.","journal-title":"Clin Epigenetics"},{"key":"2010_CR61","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3324\/haematol.2016.144964","volume":"102","author":"R Mathur","year":"2017","unstructured":"Mathur R, Sehgal L, Havranek O, K\u00f6hrer S, Khashab T, Jain N, Burger JA, Neelapu SS, Davis RE, Samaniego F. Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs. Haematologica. 2017;102:373\u201380. https:\/\/doi.org\/10.3324\/haematol.2016.144964.","journal-title":"Haematologica"},{"key":"2010_CR62","doi-asserted-by":"publisher","first-page":"6313","DOI":"10.1093\/nar\/gkac471","volume":"50","author":"M Yang","year":"2022","unstructured":"Yang M, Wang C, Zhou M, Bao L, Wang Y, Kumar A, Xing C, Luo W, Wang Y. KDM6B promotes parthanatos via suppression of O6-methylguanine DNA methyltransferase repair and sustained checkpoint response. Nucleic Acids Res. 2022;50:6313\u201331. https:\/\/doi.org\/10.1093\/nar\/gkac471.","journal-title":"Nucleic Acids Res"},{"key":"2010_CR63","doi-asserted-by":"publisher","unstructured":"Romani M, Daga A, Forlani A, Pistillo MP, Banelli B. Targeting of histone demethylases KDM5A and KDM6B inhibits the proliferation of Temozolomide-Resistant glioblastoma cells. Cancers (Basel). 2019;11. https:\/\/doi.org\/10.3390\/cancers11060878.","DOI":"10.3390\/cancers11060878"},{"key":"2010_CR64","doi-asserted-by":"publisher","first-page":"762478","DOI":"10.3389\/fcell.2021.762478","volume":"9","author":"S Hong","year":"2021","unstructured":"Hong S, Zhang Y, Cao M, Lin A, Yang Q, Zhang J, Luo P, Guo L. Hypoxic characteristic genes predict response to immunotherapy for urothelial carcinoma. Front Cell Dev Biol. 2021;9:762478. https:\/\/doi.org\/10.3389\/fcell.2021.762478.","journal-title":"Front Cell Dev Biol"},{"key":"2010_CR65","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1158\/1078-0432.Ccr-19-2230","volume":"26","author":"K Kobatake","year":"2020","unstructured":"Kobatake K, Ikeda KI, Nakata Y, Yamasaki N, Ueda T, Kanai A, Sentani K, Sera Y, Hayashi T, Koizumi M, Miyakawa Y, Inaba T, Sotomaru Y, Kaminuma O, Ichinohe T, Honda ZI, Yasui W, Horie S, Black PC, Matsubara A, Honda H. Kdm6a deficiency activates inflammatory Pathways, promotes M2 macrophage Polarization, and causes bladder cancer in Cooperation with p53 dysfunction. Clin Cancer Res. 2020;26:2065\u201379. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-2230.","journal-title":"Clin Cancer Res"},{"key":"2010_CR66","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1007\/s00262-022-03167-8","volume":"71","author":"LH Qu","year":"2022","unstructured":"Qu LH, Fang Q, Yin T, Yi HM, Mei GB, Hong ZZ, Qiu XB, Zhou R, Dong HF. Comprehensive analyses of prognostic biomarkers and immune infiltrates among histone lysine demethylases (KDMs) in hepatocellular carcinoma. Cancer Immunol Immunother. 2022;71:2449\u201367. https:\/\/doi.org\/10.1007\/s00262-022-03167-8.","journal-title":"Cancer Immunol Immunother"},{"key":"2010_CR67","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.canlet.2020.11.031","volume":"499","author":"J Yi","year":"2021","unstructured":"Yi J, Shi X, Xuan Z, Wu J. Histone demethylase UTX\/KDM6A enhances tumor immune cell recruitment, promotes differentiation and suppresses Medulloblastoma. Cancer Lett. 2021;499:188\u2013200. https:\/\/doi.org\/10.1016\/j.canlet.2020.11.031.","journal-title":"Cancer Lett"},{"key":"2010_CR68","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1158\/0008-5472.Can-22-0968","volume":"82","author":"J Yang","year":"2022","unstructured":"Yang J, Jin L, Kim HS, Tian F, Yi Z, Bedi K, Ljungman M, Pasca di Magliano M, Crawford H, Shi J. KDM6A loss recruits Tumor-Associated neutrophils and promotes neutrophil extracellular trap formation in pancreatic cancer. Cancer Res. 2022;82:4247\u201360. https:\/\/doi.org\/10.1158\/0008-5472.Can-22-0968.","journal-title":"Cancer Res"},{"key":"2010_CR69","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/s41467-024-45561-z","volume":"15","author":"J Liu","year":"2024","unstructured":"Liu J, Xing L, Li J, Wen K, Liu N, Liu Y, Wu G, Wang S, Ogiya D, Song TY, Kurata K, Penailillo J, Morelli E, Wang T, Hong X, Gulla A, Tai YT, Munshi N, Richardson P, Carrasco R, Hideshima T, Anderson KC. Epigenetic regulation of CD38\/CD48 by KDM6A mediates NK cell response in multiple myeloma. Nat Commun. 2024;15:1367. https:\/\/doi.org\/10.1038\/s41467-024-45561-z.","journal-title":"Nat Commun"},{"key":"2010_CR70","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1182\/blood.2024024518","volume":"144","author":"D Dup\u00e9r\u00e9-Richer","year":"2024","unstructured":"Dup\u00e9r\u00e9-Richer D, Riva A, Barwick BG, Maji S, Casellas Rom\u00e1n H, Li J, De U, Sobh A, Quickstad G, Piper C, Kulis M, Ezponda T, Mart\u00edn-Subero JI, Tonon G, Zhang W, Mitsiades CS, Boise LH, Bennett RL, Licht JD. KDM6A regulates immune response genes in multiple myeloma. Blood. 2024;144:1508\u201320. https:\/\/doi.org\/10.1182\/blood.2024024518.","journal-title":"Blood"},{"key":"2010_CR71","doi-asserted-by":"publisher","first-page":"166611","DOI":"10.1016\/j.bbadis.2022.166611","volume":"1869","author":"L Du","year":"2023","unstructured":"Du L, Dai B, Liu X, Zhou D, Yan H, Shen T, Wang D, Tan X. KDM6B regulates M2 polarization of macrophages by modulating the stability of nuclear \u03b2-catenin. Biochim Biophys Acta Mol Basis Dis. 2023;1869:166611. https:\/\/doi.org\/10.1016\/j.bbadis.2022.166611.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"2010_CR72","doi-asserted-by":"publisher","first-page":"6847","DOI":"10.7150\/thno.51864","volume":"11","author":"J Xun","year":"2021","unstructured":"Xun J, Du L, Gao R, Shen L, Wang D, Kang L, Chen C, Zhang Z, Zhang Y, Yue S, Feng S, Xiang R, Mi X, Tan X. Cancer-derived Exosomal miR-138-5p modulates polarization of tumor-associated macrophages through Inhibition of KDM6B. Theranostics. 2021;11:6847\u201359. https:\/\/doi.org\/10.7150\/thno.51864.","journal-title":"Theranostics"},{"key":"2010_CR73","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1038\/s43018-023-00620-0","volume":"4","author":"S Goswami","year":"2023","unstructured":"Goswami S, Raychaudhuri D, Singh P, Natarajan SM, Chen Y, Poon C, Hennessey M, Tannir AJ, Zhang J, Anandhan S, Kerrigan BP, Macaluso MD, He Z, Jindal S, Lang FF, Basu S, Sharma P. Myeloid-specific KDM6B Inhibition sensitizes glioblastoma to PD1 Blockade. Nat Cancer. 2023;4:1455\u201373. https:\/\/doi.org\/10.1038\/s43018-023-00620-0.","journal-title":"Nat Cancer"},{"key":"2010_CR74","doi-asserted-by":"publisher","first-page":"9050","DOI":"10.1038\/s41467-024-53233-1","volume":"15","author":"K Zhang","year":"2024","unstructured":"Zhang K, Liu K, Hu B, Du G, Chen X, Xiao L, Zhang Y, Jiang L, Jing N, Cheng C, Wang J, Xu P, Wang Y, Ma P, Zhuang G, Zhao H, Sun Y, Wang D, Wang Q, Xue W, Gao WQ, Zhang P, Zhu HH. Iron-loaded cancer-associated fibroblasts induce immunosuppression in prostate cancer. Nat Commun. 2024;15:9050. https:\/\/doi.org\/10.1038\/s41467-024-53233-1.","journal-title":"Nat Commun"},{"key":"2010_CR75","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41375-023-01833-z","volume":"37","author":"LD Boila","year":"2023","unstructured":"Boila LD, Ghosh S, Bandyopadhyay SK, Jin L, Murison A, Zeng AGX, Shaikh W, Bhowmik S, Muddineni S, Biswas M, Sinha S, Chatterjee SS, Mbong N, Gan OI, Bose A, Chakraborty S, Arruda A, Kennedy JA, Mitchell A, Lechman ER, Banerjee D, Milyavsky M, Minden MD, Dick JE, Sengupta A. KDM6 demethylases integrate DNA repair gene regulation and loss of KDM6A sensitizes human acute myeloid leukemia to PARP and BCL2 Inhibition. Leukemia. 2023;37:751\u201364. https:\/\/doi.org\/10.1038\/s41375-023-01833-z.","journal-title":"Leukemia"},{"key":"2010_CR76","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1101\/gad.351408.123","volume":"38","author":"LD Caeiro","year":"2024","unstructured":"Caeiro LD, Nakata Y, Borges RL, Zha M, Garcia-Martinez L, Ba\u00f1uelos CP, Stransky S, Liu T, Chan HL, Brabson J, Dom\u00ednguez D, Zhang Y, Lewis PW, Aznar Benitah S, Cimmino L, Bilbao D, Sidoli S, Wang Z, Verdun RE, Morey L. Methylation of histone H3 lysine 36 is a barrier for therapeutic interventions of head and neck squamous cell carcinoma. Genes Dev. 2024;38:46\u201369. https:\/\/doi.org\/10.1101\/gad.351408.123.","journal-title":"Genes Dev"},{"key":"2010_CR77","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.cell.2015.04.048","volume":"161","author":"MC Whittle","year":"2015","unstructured":"Whittle MC, Izeradjene K, Rani PG, Feng L, Carlson MA, DelGiorno KE, Wood LD, Goggins M, Hruban RH, Chang AE, Calses P, Thorsen SM, Hingorani SR. RUNX3 controls a metastatic switch in pancreatic ductal adenocarcinoma. Cell. 2015;161:1345\u201360. https:\/\/doi.org\/10.1016\/j.cell.2015.04.048.","journal-title":"Cell"},{"key":"2010_CR78","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.ccell.2018.02.003","volume":"33","author":"J Andricovich","year":"2018","unstructured":"Andricovich J, Perkail S, Kai Y, Casasanta N, Peng W, Tzatsos A. Loss of KDM6A activates Super-Enhancers to induce Gender-Specific Squamous-like pancreatic cancer and confers sensitivity to BET inhibitors. Cancer Cell. 2018;33:512\u2013e526518. https:\/\/doi.org\/10.1016\/j.ccell.2018.02.003.","journal-title":"Cancer Cell"},{"key":"2010_CR79","doi-asserted-by":"publisher","unstructured":"Duan N, Hua Y, Yan X, He Y, Zeng T, Gong J, Fu Z, Li W, Yin Y. An imbalance in histone modifiers induces tRNA-Cys-GCA overexpression and tRF-27 accumulation by attenuating promoter H3K27me3 in primary Trastuzumab-Resistant breast cancer. Cancers (Basel). 2024;16. https:\/\/doi.org\/10.3390\/cancers16061118.","DOI":"10.3390\/cancers16061118"},{"key":"2010_CR80","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.7150\/thno.50571","volume":"11","author":"C Zhang","year":"2021","unstructured":"Zhang C, Shen L, Zhu Y, Xu R, Deng Z, Liu X, Ding Y, Wang C, Shi Y, Bei L, Wei D, Thorne RF, Zhang XD, Yu L, Chen S. KDM6A promotes Imatinib resistance through YY1-mediated transcriptional upregulation of TRKA independently of its demethylase activity in chronic myelogenous leukemia. Theranostics. 2021;11:2691\u2013705. https:\/\/doi.org\/10.7150\/thno.50571.","journal-title":"Theranostics"},{"key":"2010_CR81","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.stem.2016.11.003","volume":"20","author":"BB Liau","year":"2017","unstructured":"Liau BB, Sievers C, Donohue LK, Gillespie SM, Flavahan WA, Miller TE, Venteicher AS, Hebert CH, Carey CD, Rodig SJ, Shareef SJ, Najm FJ, van Galen P, Wakimoto H, Cahill DP, Rich JN, Aster JC, Suv\u00e0 ML, Patel AP, Bernstein BE. Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance. Cell Stem Cell. 2017;20:233\u2013e246237. https:\/\/doi.org\/10.1016\/j.stem.2016.11.003.","journal-title":"Cell Stem Cell"},{"key":"2010_CR82","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12920-020-00794-x","volume":"13","author":"Z Tong","year":"2020","unstructured":"Tong Z, Yan C, Dong YA, Yao M, Zhang H, Liu L, Zheng Y, Zhao P, Wang Y, Fang W, Zhang F, Jiang W. Whole-exome sequencing reveals potential mechanisms of drug resistance to FGFR3-TACC3 targeted therapy and subsequent drug selection: towards a personalized medicine. BMC Med Genomics. 2020;13:138. https:\/\/doi.org\/10.1186\/s12920-020-00794-x.","journal-title":"BMC Med Genomics"},{"key":"2010_CR83","doi-asserted-by":"publisher","first-page":"e1452","DOI":"10.1002\/ctm2.1452","volume":"13","author":"W Guo","year":"2023","unstructured":"Guo W, Li S, Qian Y, Li L, Wang F, Tong Y, Li Q, Zhu Z, Gao WQ, Liu Y. KDM6A promotes hepatocellular carcinoma progression and dictates lenvatinib efficacy by upregulating FGFR4 expression. Clin Transl Med. 2023;13:e1452. https:\/\/doi.org\/10.1002\/ctm2.1452.","journal-title":"Clin Transl Med"},{"key":"2010_CR84","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.cell.2014.06.049","volume":"158","author":"KA Hoadley","year":"2014","unstructured":"Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MDM, Niu B, McLellan MD, Uzunangelov V, Zhang J, Kandoth C, Akbani R, Shen H, Omberg L, Chu A, Margolin AA, Van\u2019t Veer LJ, Lopez-Bigas N, Laird PW, Raphael BJ, Ding L, Robertson AG, Byers LA, Mills GB, Weinstein JN, Van Waes C, Chen Z, Collisson EA, Benz CC, Perou CM, Stuart JM. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014;158:929\u201344. https:\/\/doi.org\/10.1016\/j.cell.2014.06.049.","journal-title":"Cell"},{"key":"2010_CR85","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Comprehensive molecular portraits of human breast tumours","year":"2012","unstructured":"Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61\u201370. https:\/\/doi.org\/10.1038\/nature11412.","journal-title":"Nature"},{"key":"2010_CR86","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1021\/acsptsci.2c00212","volume":"6","author":"A Mehmood","year":"2023","unstructured":"Mehmood A, Nawab S, Jin Y, Hassan H, Kaushik AC, Wei DQ. Ranking breast cancer drugs and biomarkers identification using machine learning and pharmacogenomics. ACS Pharmacol Transl Sci. 2023;6:399\u2013409. https:\/\/doi.org\/10.1021\/acsptsci.2c00212.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"2010_CR87","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1038\/s41419-020-03279-y","volume":"11","author":"C Macedo-Silva","year":"2020","unstructured":"Macedo-Silva C, Miranda-Gon\u00e7alves V, Lameirinhas A, Lencart J, Pereira A, Lobo J, Guimar\u00e3es R, Martins AT, Henrique R, Bravo I, Jer\u00f3nimo C. JmjC-KDMs KDM3A and KDM6B modulate radioresistance under hypoxic conditions in esophageal squamous cell carcinoma. Cell Death Dis. 2020;11:1068. https:\/\/doi.org\/10.1038\/s41419-020-03279-y.","journal-title":"Cell Death Dis"},{"key":"2010_CR88","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41392-023-01639-6","volume":"8","author":"C Macedo-Silva","year":"2023","unstructured":"Macedo-Silva C, Miranda-Gon\u00e7alves V, Tavares NT, Barros-Silva D, Lencart J, Lobo J, Oliveira \u00c2, Correia MP, Altucci L, Jer\u00f3nimo C. Epigenetic regulation of TP53 is involved in prostate cancer radioresistance and DNA damage response signaling. Signal Transduct Target Ther. 2023;8:395. https:\/\/doi.org\/10.1038\/s41392-023-01639-6.","journal-title":"Signal Transduct Target Ther"},{"key":"2010_CR89","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1182\/bloodadvances.2021006881","volume":"7","author":"AL Levinson","year":"2023","unstructured":"Levinson AL, Tjoa K, Huang B, Meyer LK, Kim MO, Brady SW, Zhang J, Shannon K, Wandler AM. Opposing effects of KDM6A and JDP2 on glucocorticoid sensitivity in T-ALL. Blood Adv. 2023;7:3479\u201384. https:\/\/doi.org\/10.1182\/bloodadvances.2021006881.","journal-title":"Blood Adv"},{"key":"2010_CR90","doi-asserted-by":"publisher","first-page":"e12772","DOI":"10.1111\/acel.12772","volume":"17","author":"E Cuy\u00e0s","year":"2018","unstructured":"Cuy\u00e0s E, Verdura S, Llorach-Pares L, Fern\u00e1ndez-Arroyo S, Luciano-Mateo F, Cabr\u00e9 N, Stursa J, Werner L, Martin-Castillo B, Viollet B, Neuzil J, Joven J, Nonell-Canals A, Sanchez-Martinez M, Menendez JA. Metformin directly targets the H3K27me3 demethylase KDM6A\/UTX. Aging Cell. 2018;17:e12772. https:\/\/doi.org\/10.1111\/acel.12772.","journal-title":"Aging Cell"},{"key":"2010_CR91","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1039\/c3sc51122g","volume":"4","author":"RJ Hopkinson","year":"2013","unstructured":"Hopkinson RJ, Tumber A, Yapp C, Chowdhury R, Aik W, Che KH, Li XS, Kristensen JBL, King ONF, Chan MC, Yeoh KK, Choi H, Walport LJ, Thinnes CC, Bush JT, Lejeune C, Rydzik AM, Rose NR, Bagg EA, McDonough MA, Krojer T, Yue WW, Ng SS, Olsen L, Brennan PE, Oppermann U, Muller-Knapp S, Klose RJ, Ratcliffe PJ, Schofield CJ, Kawamura A. 5-Carboxy-8-hydroxyquinoline is a broad spectrum 2-Oxoglutarate Oxygenase inhibitor which causes iron translocation. Chem Sci. 2013;4:3110\u20137. https:\/\/doi.org\/10.1039\/c3sc51122g.","journal-title":"Chem Sci"},{"key":"2010_CR92","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/nature11262","volume":"488","author":"L Kruidenier","year":"2012","unstructured":"Kruidenier L, Chung CW, Cheng Z, Liddle J, Che K, Joberty G, Bantscheff M, Bountra C, Bridges A, Diallo H, Eberhard D, Hutchinson S, Jones E, Katso R, Leveridge M, Mander PK, Mosley J, Ramirez-Molina C, Rowland P, Schofield CJ, Sheppard RJ, Smith JE, Swales C, Tanner R, Thomas P, Tumber A, Drewes G, Oppermann U, Patel DJ, Lee K, Wilson DM. A selective Jumonji H3K27 demethylase inhibitor modulates the Proinflammatory macrophage response. Nature. 2012;488:404\u20138. https:\/\/doi.org\/10.1038\/nature11262.","journal-title":"Nature"},{"key":"2010_CR93","doi-asserted-by":"publisher","first-page":"4802","DOI":"10.1038\/s41598-019-39214-1","volume":"9","author":"V Khodaverdian","year":"2019","unstructured":"Khodaverdian V, Tapadar S, MacDonald IA, Xu Y, Ho PY, Bridges A, Rajpurohit P, Sanghani BA, Fan Y, Thangaraju M, Hathaway NA, Oyelere AK. Deferiprone: Pan-selective histone lysine demethylase Inhibition activity and structure activity relationship study. Sci Rep. 2019;9:4802. https:\/\/doi.org\/10.1038\/s41598-019-39214-1.","journal-title":"Sci Rep"},{"key":"2010_CR94","doi-asserted-by":"publisher","first-page":"993775","DOI":"10.3389\/fonc.2022.993775","volume":"12","author":"XD Zhong","year":"2022","unstructured":"Zhong XD, Chen LJ, Xu XY, Liu YJ, Tao F, Zhu MH, Li CY, Zhao D, Yang GJ, Chen J. Berberine as a potential agent for breast cancer therapy. Front Oncol. 2022;12:993775. https:\/\/doi.org\/10.3389\/fonc.2022.993775.","journal-title":"Front Oncol"},{"key":"2010_CR95","doi-asserted-by":"publisher","unstructured":"Yang GJ, Ko CN, Zhong HJ, Leung CH, Ma DL. Structure-Based discovery of a selective KDM5A inhibitor that exhibits Anti-Cancer activity via inducing cell cycle arrest and senescence in breast cancer cell lines. Cancers (Basel). 2019;11. https:\/\/doi.org\/10.3390\/cancers11010092.","DOI":"10.3390\/cancers11010092"},{"key":"2010_CR96","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1158\/1535-7163.Mct-17-0802","volume":"17","author":"W Wang","year":"2018","unstructured":"Wang W, Lim KG, Feng M, Bao Y, Lee PL, Cai Y, Chen Y, Zhang H, Marzese D, Hoon DSB, Yu Q. KDM6B counteracts EZH2-Mediated suppression of IGFBP5 to confer resistance to PI3K\/AKT inhibitor treatment in breast cancer. Mol Cancer Ther. 2018;17:1973\u201383. https:\/\/doi.org\/10.1158\/1535-7163.Mct-17-0802.","journal-title":"Mol Cancer Ther"},{"key":"2010_CR97","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1038\/ncb3410","volume":"18","author":"M Pan","year":"2016","unstructured":"Pan M, Reid MA, Lowman XH, Kulkarni RP, Tran TQ, Liu X, Yang Y, Hernandez-Davies JE, Rosales KK, Li H, Hugo W, Song C, Xu X, Schones DE, Ann DK, Gradinaru V, Lo RS, Locasale JW, Kong M. Regional glutamine deficiency in tumours promotes dedifferentiation through Inhibition of histone demethylation. Nat Cell Biol. 2016;18:1090\u2013101. https:\/\/doi.org\/10.1038\/ncb3410.","journal-title":"Nat Cell Biol"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-02010-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-025-02010-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-02010-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T15:29:48Z","timestamp":1763738988000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-025-02010-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":97,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2010"],"URL":"https:\/\/doi.org\/10.1186\/s13148-025-02010-y","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"198"}}